Cel­gene, Google dou­ble down on Ar­mo’s PhI­II im­muno-on­col­o­gy drug with $67M round

Ar­mo Bio­Sciences has lined up a big $67 mil­lion C round to pay for the late-stage de­vel­op­ment of some of its im­muno-on­col­o­gy as­sets.

Launched and built with the help of some mar­quee in­vestors like Cel­gene, Klein­er Perkins, GV (Google) and Or­biMed, Ar­mo has now at­tract­ed some ma­jor league Chi­nese VCs to its pipeline work. Qim­ing Ven­ture Part­ners led the round with help from new in­vestors Decheng Cap­i­tal, Se­quoia Cap­i­tal, Quan Cap­i­tal and RTW In­vest­ments. All the orig­i­nal back­ers came back in for the C round.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER